Pain
Conditions
Brief summary
Study to determine the kinetic of the analgesic effect of 500 mg and 1000 mg of Eschscholtzia Californica per os and placebo in patients undergoing dental surgery over an observation period of 6 hours. In a secondary analysis, kinetic of analgesic effect comparison between Eschscholtzia californica 500 mg, 1000 mg and Ibuprofen 200 mg
Interventions
DRUGEschscholtzia Californica - low dose
DRUGEschscholtzia Californica - high dose
DRUGIbuprofen
DRUGEschscholtzia Californica - low dose Placebo
DRUGEschscholtzia Californica - high dose Placebo
Sponsors
Boehringer Ingelheim
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Male or female above 18 or below 61 years old * Patient having to undergo a third molar removal from the lower jaw under local troncular anesthesia (articaine + adrenaline) * Type of inclusion of the molar: * Molar in the sub-mucosa: Type II * Molar partially impacted in the bone: Type III * Patient suffering from at least moderate to severe pain after surgical removal of an impacted third molar, defined by a 4 point verbal rating scale * Patient's informed consent in accordance with the French legislation * Patient affiliated to the Social Security System
Exclusion criteria
* Pregnant or nursing female or female of childbearing potential not using a medically approved method of contraception like oral contraception or intrauterine contraceptive device * Patient with any pathology inducing a chronic pain * Patient having taken any drug with analgesic properties in the 24 hours previous to the administration of the study drug * Patient with concomitant administration of other Non-Steroid Anti-Inflammatory Drug(s) (NSAIDs) or analgesic agents * Patients treated by an antibiotic different from those required for the dental surgery which administration is started 48 hours prior to the tooth removal * Patient with significant peri-operative complication judged by the investigator * Patient with anti-coagulants concomitant treatment (including heparin) * Patient with severe hepatic or renal insufficiency which judged to be regarded as clinically relevant by the investigator or any known clinically significant disease which may induce a risk for the patient in participating to the trial * Patient with mental disturbance * Patient with non controlled diabetes * Patient with acute infections * Patient with respiratory insufficiency, asthma * Patient unable to comply with the protocol * Patient having taken part in a clinical trial in the past month or already participating in another trial * Patient deprived of their freedom by a judicial or administrative decision * Adults under guardianship * Persons hospitalized in medical or social establishments * Patients in emergency situation * Patient with a known or suspected hypersensitivity to the trial medication, to Ibuprofen, Paracetamol, anesthetic used (articaine, adrenaline), to the preventive antibiotic treatment (penicillin, macrolides) Post study exclusion period: the patient will not be able to participate in any other trial for a period of two weeks after the end of this trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VAS-SPID - summed pain intensity differences (SPID) on a VAS (Visual Analogue Scale) | Baseline, up to 6 hours after drug intake |
Secondary
| Measure | Time frame |
|---|---|
| Number of patients requiring a rescue medication | Day 1 |
| Pain intensity differences (PID) on a VAS | Baseline, up to 6 hours after drug intake |
| Pain intensity difference in the groups on a VAS | Baseline, 2 hours after drug intake |
| Time point for maximum pain intensity difference on VAS | Baseline, up to 6 hours after drug intake |
| Number of patients with a pain decrease of at least 50 % over the all period of observation on a VAS | Baseline, up to 6 hours after drug intake |
| Number of patients with adverse events | up to 9 days after treatment |
| Total pain relief on a 5-point VRS | up to 6 hours after drug intake |
| Global efficacy assessment on a 4-points VRS | 2 and 6 hours after drug intake, day 7 |
| Assessment of tolerability by investigator on a 4-point VRS | 6 hours after drug intake, day 7 |
| Assessment of tolerability by subject on a 4-point VRS | 6 hours after drug intake, day 7 |
| Pain relief at each observed time points on a 5-point verbal rating scale (VRS) | up to 6 hours after drug intake |
Outcome results
None listed